Gammagard® and reported hepatitis C virus episodes

Clinical Therapeutics

Volumn 18, Issue SUPPL. B, 1996, Pages 3-8

  Gomperts, Edward D ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DETERGENT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; SOLVENT;

CLASSIFICATION; CONFERENCE PAPER; DONOR; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD AND DRUG ADMINISTRATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; VIRUS TRANSMISSION; ISOLATION AND PURIFICATION; REVIEW; UNITED STATES;

HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; UNITED STATES;

EID: 0029658195     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80192-5     Document Type: Conference Paper

References (14)

1. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: A randomized controlled clinical trial. NEJM. 1988;319: 902-907.
2. van der Meche FG, Schmitz PI, and the Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. NEJM. 1992; 326:1123-1129.
3. The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. NEJM. 1992;327:234-240.
4. Baker CJ, Melish ME, Hall RT, et al. The Multicenter Group for the Study of Immune Globulin in Neonates. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. NEJM. 1992;327:213-219.
5. Lee ML, Courter SG, Tait D, Kingdon HS. Long-term evaluation of intravenous immune globulin preparation with regard to non-A, non-B hepatitis safety. In: Zuckerman AJ, ed. Viral Hepatitis and Liver Disease. New York: Alan R. Liss; 1988: 596-599.
6. Oomes PG, van des Meahe FGA, Kleyweg RP. Liver function disturbances in Guillain-Barre syndrome: A prospective longitudinal study in 100 patients. Neurology. 1996;46:96-100.
7. Cunningham-Rundles C, Zhou Z, Mankarious S, Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol. 1993;13: 272-278.
8. Murdoch A. Irish mothers called for hepatitis C virus screening. BMJ. 1994:308: 613-614.
9. Ochs HD, Fischer SH, Virant FS, et al. Non-A non-B hepatitis and intravenous immunoglobulin. Lancet. 1985;1:404-405.
10. Weiland O, Mattsson L, Glaumann H. Non-A non-B hepatitis after intravenous gamma globulin. Lancet. 1986;1:976-977. Letter.
11. Lane RS. Non-A non-B hepatitis from intravenous immunoglobulin. Lancet. 1983; 2:974-975. Letter.
12. Lever AM, Webster AD, Brown D, Thomas HC. Non-A non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet. 1984;2:1062-1064.
13. Finlayson JS, Tankersley DL. Anti-HCV screening and plasma fractionation: The case against. Lancet. 1990;335:1274-1275. Letter.
14. Centers for Disease Control. Outbreak of hepatitis C associated with intravenous immunoglobulin administration: United States, October 1993-June 1994. MMWR. 1994;43:505-509.